Biocon Biologics bags Rs 689 crore contract for Insugen from Malaysian Govt

Biocon Sdn. Bhd. a subsidiary of Biocon Biologics in Malaysia, will manufacture and supply its range of insulins to its partner Duopharma Marketing Sdn. Bhd. (DMktg), a subsidiary of Duopharma Biotech, a pharmaceutical & biotech company in Malaysia.

Biocon Biologics' Insugen formulations will be available to patients at all Ministry of Health hospitals, district health offices and health clinics.

Susheel Urnesh, Chief Commercial Officer, Emerging Markets, Biocon Biologics, said: "We are pleased to renew our commitment to provide affordable access to our recombinant human insulin for people with diabetes in Malaysia through this new government contract. This will enable us to serve over 400,000 people with diabetes using recombinant human insulin, helping the government in its journey towards equitable access to diabetes care."

Read also: Honour- Glasgow University research centre named after Biocon founders

The rh-Insulin formulations, Insugen-R, Insugen-N and lnsugen-30/70, are manufactured at Biocon Sdn. Bhd.'s Johor facility and have been approved by the National Pharmaceutical Regulatory Authority (NPRA), Malaysia.

Biocon Biologics has created a Center of Excellence (CoE) for insulins in Malaysia with end-to-end capabilities to manufacture a broad portfolio of regular, basal and rapid insulins. More recently, Biocon's biosimilar insulin Glargine made at Malaysia, has received a historic U.S. FDA approval as the `first interchangeable biosimilar'.